Next-generation treatments for Alzheimer's disease
Leveraging Genetically Encoded engiNeered protEins foR Next-Generation alzheImer'S Therapeutics
This study is testing new treatments for Alzheimer's disease that aim to improve memory and learning by enhancing brain connections at a cellular level.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 14 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Locations | 1 site (Roma) |
| Trial ID | NCT06372587 on ClinicalTrials.gov |
What this trial studies
This study explores innovative approaches to treating Alzheimer's disease (AD) by focusing on the mechanisms of synaptic plasticity, which are crucial for learning and memory. Given the failures of previous trials targeting amyloid and tau proteins, this research aims to develop genetically encoded engineered proteins that may enhance neuronal connections. The study seeks to address the heterogeneous nature of AD by intervening at a cellular level to potentially improve cognitive function. Participants will be closely monitored to assess the efficacy of these new therapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 80 who have been clinically diagnosed with probable Alzheimer's disease.
Not a fit: Patients with other neurological disorders, coagulation issues, or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective treatments for Alzheimer's disease, improving cognitive function and quality of life for patients.
How similar studies have performed: While previous studies have focused on amyloid and tau proteins, this novel approach targeting synaptic plasticity has not been extensively tested, making it a potentially groundbreaking direction in Alzheimer's research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Manifest clinical criteria for probable AD; * Age between 18 and 80 years; * Signed informed consent obtained; Exclusion Criteria: * Patients suffering from other neurological diseases; * Patients with coagulation disorders or in treatment with anticoagulant drugs; * Patients suffering from dermatological diseases and connective tissue diseases; * Patients suffering from other organic, psychiatric diseases or laboratory abnormalities could preclude participation or invalidate the study results; * Inability to give informed consent.
Where this trial is running
Roma
- Fondazione Policlinico Universitario A. Gemelli IRCCS — Roma, Italy (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.